# Study of XL647 Administered Orally Daily to Patients With Solid Tumors

> **NCT00336765** · PHASE1 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 31 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** XL647

## Key facts

- **NCT ID:** NCT00336765
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336765, "Study of XL647 Administered Orally Daily to Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00336765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*